Previously, Eliquis was only approved to reduce the risk of stroke and blood clots for patients with atrial fibrilliation not caused by a heart valve problem.
More Articles on FDA Approvals:
FDA Approves Migraine ‘Headband’ for Marketing
FDA Approves Myalept to Treat Lipodystrophy Complications
Medtronic Receives FDA 510(k) Clearance for Reveal LINQ Insertable Cardiac Monitor
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
